First-line bevacizumab (B) plus paclitaxel (P) in HER2-negative (HER2-ve) metastatic breast cancer (mBC): Efficacy and safety in an Italian multicenter retrospective study

被引：0
作者：
Andreis, D.
Scandurra, G.
Santini, D.
Gucciardino, C.
La Verde, N. M.
Girelli, S.
Alabiso, I.
Saetta, A.
Atzori, F.
Collova, E.
Ferzi, A.
Gori, S.
Lipari, H.
Saggia, C.
Marcon, I.
Generali, D. G.
机构：
[1] AO Ist Ospitalieri Cremona, UO Multidisciplinare Patol Mammaria, Cremona, Italy
[2] Day Hop, Humanitas Ctr Catanese Oncol, Catania, Italy
[3] Univ Campus Biomed Roma, Dipartimento Med Oncol, Rome, Italy
[4] AO Fatebenefratelli & Oftalm, UO Oncol Med, Milan, Italy
[5] Univ Turin, Dipartimento Sci Clin & Biol, Turin, Italy
[6] Fdn Ist San Raffaele D Giglio di Cefalu, UO Oncol, Cefalu, Italy
[7] AOU Cagliari, Struttura Complessa Oncol Med, Cagliari, Italy
[8] Osped Civile Legnano, Legnano, Italy
[9] AO Perugia, Oncol Med, Perugia, Italy
[10] Cannizzaro Hosp, Div Med Oncol, Catania, Italy
[11] AOU Osped Maggiore della Carita, SCDU Oncol, Novara, Italy
[12] AO Osped Circolo, UO Oncol, Varese, Italy
[13] Fdn Macchi, Varese, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.e11502
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e11502
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Efficacy and Safety of First-Line Bevacizumab (BEV) Combined with Paclitaxel (PAC) According to Age: Subpopulation Analysis of a Large, Multicenter, Non-Interventional Study in Patients (Pts) with HER2-Negative Metastatic Breast Cancer (MBC).
    Geberth, M.
    Foerster, F.
    Klare, P.
    Schneeweiss, A.
    Schumacher, C.
    Hahn, L.
    Tesch, H.
    Hertz-Eichenrode, M. M.
    Weinberg, R.
    Gluz, O.
    Kuemmel, S.
    Strumberg, D.
    Wuelfing, P.
    Schmidt, M.
    CANCER RESEARCH, 2009, 69 (24) : 851S - 852S
  • [22] Efficacy of first-line bevacizumab (Bev) combined with weekly paclitaxel (wPac) for HER2-negative metastatic breast cancer (MBC): Results of a Japanese phase II study (n=120)
    Ito, Y.
    Aogi, K.
    Masuda, N.
    Ohno, S.
    Oda, T.
    Iwata, H.
    Kashiwaba, M.
    Fujiwara, Y.
    Kamigaki, S.
    Ueno, T.
    Takashima, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [23] Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER2-negative breast cancer
    Babacan, Taner
    Efe, Orhan
    Hasirci, Ahmet S.
    Demirci, Fatih
    Buyukhatipoglu, Hakan
    Balakan, Ozan
    Sarici, Furkan
    Kertmen, Neyran
    Esin, Ece
    Akin, Serkan
    Ates, Ozturk
    Aksoy, Sercan
    Sever, Ali R.
    Altundag, Kadri
    TUMORI JOURNAL, 2015, 101 (04): : 418 - 423
  • [24] PACLITAXEL (P) AND BEVACIZUMAB (BEV), AS FIRST-LINE CHEMOTHERAPY, IN PATIENTS WITH HER2-NEGATIVE METASTATIC BREAST CANCER (MBC). THE HELLENIC COOPERATIVE ONCOLOGY GROUP EXPERIENCE WITH BIOMARKER EVALUATION
    Kourea, H. P.
    Koutras, A. K.
    Kotoula, V.
    Bobos, M.
    Fountzila, A. Kalogera
    Papazisis, K. T.
    Christodoulou, C.
    Res, E.
    Bournakis, E.
    Fountzilas, G.
    ANNALS OF ONCOLOGY, 2010, 21 : 104 - 104
  • [25] Primary endpoints in first-line trials in patients with HER2-negative/-unknown metastatic breast cancer (MBC)
    Kuemmel, S.
    Mueller, V
    Lux, M. P.
    Weyer, G.
    Pintoffl, J. P.
    Jackisch, C.
    ONKOLOGIE, 2012, 35 : 66 - +
  • [26] An Evaluation of the Safety and Efficacy of Lapatinib Plus Trastuzumab Plus Paclitaxel in First-Line HER2+Metastatic Breast Cancer
    Esteva, F. J.
    Franco, S. X.
    Hagan, M. K.
    Somer, R. A.
    Dombroski, C. S.
    Florance, A. M.
    Turner, S. J.
    Stein, S.
    Perez, A.
    CANCER RESEARCH, 2009, 69 (24) : 793S - 793S
  • [27] First-line bevacizumab and eribulin combination therapy for HER2-negative metastatic breast cancer: Efficacy and safety in the GINECO phase II ESMERALDA study
    Hardy-Bessard, Anne-Claire
    Brocard, Fabien
    Clatot, Florian
    Lortholary, Alain
    You, Benoit
    Grenier, Julien
    Martin-Babau, Jerome
    Lucas, Brigitte
    Meunier, Jerome
    Ferrero, Jean-Marc
    Savoye, Aude-Marie
    Marti, Adina
    Despax, Raymond
    Moullet, Isabelle
    Emile, George
    BREAST, 2020, 54 : 256 - 263
  • [28] Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy
    Alessandra Fabi
    Michelangelo Russillo
    Gianluigi Ferretti
    Giulio Metro
    Cecilia Nisticò
    Paola Papaldo
    Ferdinando De Vita
    Giuliana D’Auria
    Antonello Vidiri
    Diana Giannarelli
    Francesco Cognetti
    BMC Cancer, 12
  • [29] A multicenter phase I-II study of docetaxel plus epirubicin plus bevacizumab as first-line treatment in women with HER2-negative metastatic breast cancer
    Tryfonidis, K.
    Boukovinas, I.
    Xenidis, N.
    Christophyllakis, C.
    Papakotoulas, P.
    Politaki, E.
    Malamos, N.
    Polyzos, A.
    Kakolyris, S.
    Georgoulias, V.
    Mavroudis, D.
    BREAST, 2013, 22 (06) : 1171 - 1177
  • [30] Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer
    J. Salvador
    L. Manso
    J. de la Haba
    A. Jaen
    E. Ciruelos
    M. C. de Villena
    M. Gil
    A. Murias
    A. Galan
    C. Jara
    J. Bayo
    J. M. Baena
    J. Casal
    J. R. Mel
    I. Blancas
    P. Sanchez Rvira
    Clinical and Translational Oncology, 2015, 17 : 160 - 166
12345